Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases

Current Medicinal Chemistry

Volumn 18, Issue 15, 2011, Pages 2257-2262

  Prendergast, G C ^a,b,c   Chang, M Y ^a   Mandik Nayak, L ^a   Metz, R ^d   Muller, A J ^a,c  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NewLink Genetics Corporation   (United States)

Author keywords

IDO; IDO2; Immune escape; Immunoediting; Immunosuppression

Indexed keywords

ANTINEOPLASTIC AGENT; CELECOXIB; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; PYRUVIC ACID ETHYL ESTER; TRYPTOPHAN TRANSFER RNA LIGASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CELLULAR IMMUNITY; CHRONIC ARTHRITIS; CHRONIC INFLAMMATION; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; ENZYME INDUCTION; ENZYME MECHANISM; GENETIC VARIABILITY; HEALTH SURVEY; HUMAN; IMMUNIZATION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; INTESTINE SECRETION; NONHUMAN; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; RHEUMATOID ARTHRITIS; SKIN CANCER; SKIN CARCINOGENESIS; SUPPRESSOR CELL; TH2 CELL; TUMOR MICROENVIRONMENT;

EID: 79957963254     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795656072     Document Type: Article

References (63)

1. Engels, E.A.; Wu, X.; Gu, J.; Dong, Q.; Liu, J.; Spitz, M.R. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer. Res., 2007, 67(13), 6520-6527. (Pubitemid 47037538)
2. Katz, J.B.; Muller, A.J.; Metz, R.; Prendergast, G.C. Indoleamine 2,3- dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev., 2008, 222, 206-221. (Pubitemid 351430372)
3. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science., 1998, 281, 1191-1193. (Pubitemid 28406294)
4. Metz, R.; DuHadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor IDO inhibitory compound D-1MT. Cancer. Res., 2007, 67, 7082-7087. (Pubitemid 47206533)
5. Munn, D.H.; Sharma, M.D.; Baban, B.; Harding, H.P.; Zhang, Y.; Ron, D.; Mellor, A.L. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity., 2005, 22(5), 633-642. (Pubitemid 40719198)
6. Fallarino, F.; Grohmann, U.; You, S.; McGrath, B.C.; Cavener, D.R.; Vacca, C.; Orabona, C.; Bianchi, R.; Belladonna, M.L.; Volpi, C.; Santamaria, P.; Fioretti, M.C.; Puccetti, P. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol., 2006, 176(11), 6752-6761. (Pubitemid 43787857)
7. Sharma, M.D.; Baban, B.; Chandler, P.; Hou, D.Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B.R.; Mellor, A.L.; Munn, D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest., 2007, 117(9), 2570-2582. (Pubitemid 47494358)
8. Orabona, C.; Pallotta, M.T.; Volpi, C.; Fallarino, F.; Vacca, C.; Bianchi, R.; Belladonna, M.L.; Fioretti, M.C.; Grohmann, U.; Puccetti, P. SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(52), 20828-20833.
9. Grohmann, U.; Orabona, C.; Fallarino, F.; Vacca, C.; Calcinaro, F.; Falorni, A.; Candeloro, P.; Belladonna, M.L.; Bianchi, R.; Fioretti, M.C.; Puccetti, P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol., 2002, 3(11), 1097-1101. (Pubitemid 35363664)
10. Munn, D.H.; Sharma, M.D.; Lee, J.R.; Jhaver, K.G.; Johnson, T.S.; Keskin, D.B.; Marshall, B.; Chandler, P.; Antonia, S.J.; Burgess, R.; Slingluff, C.L. Jr.; Mellor, A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science., 2002, 297(5588), 1867-1870. (Pubitemid 35024345)
11. Fallarino, F.; Grohmann, U.; Hwang, K.W.; Orabona, C.; Vacca, C.; Bianchi, R.; Belladonna, M.L.; Fioretti, M.C.; Alegre, M.L.; Puccetti, P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol., 2003, 4(12), 1206-1212. (Pubitemid 37547898)
12. Taylor, M.W.; Feng, G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB. J., 1991, 5(11), 2516-2522. (Pubitemid 21905800)
13. Sugimoto, H.; Oda, S.I.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y. Crystal structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl. Acad. Sci. USA., 2006, 103(8), 2611-2616.
14. Sono, M. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. Biochemistry., 1989, 28(13), 5400-5407. (Pubitemid 19175748)
15. Kadoya, A.; Tone, S.; Maeda, H.; Minatogawa, Y.; Kido, R. Gene structure of human indoleamine 2,3-dioxygenase. Biochem. Biophys. Res. Commun., 1992, 189(1), 530-536. (Pubitemid 23030073)
16. Najfeld, V.; Menninger, J.; Muhleman, D.; Comings, D.E.; Gupta, S.L. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12->p11 by fluorescent in situ hybridization. Cytogenet. Cell. Genet., 1993, 64(3-4), 231-232. (Pubitemid 23309628)
17. Arefayene, M. Philips, S. Cao D. Mamidipalli, S. Flockhart, D.A. Wilkes, D.S. Skaar, T.C. Identification of genetic variants in the human indoleamine 2,3-dioxygenase (INDO) gene that have altered enzymatic activity. in press.
18. Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene., 2007, 396(1), 203-213. (Pubitemid 46818792)
19. Muller, A.J. Metz, R. and Prendergast G.C. Differential targeting of tryptophan catabolism in tumors and in tumor-draining lymph nodes by stereoisomers of the IDO inhibitor 1-methyl-tryptophan. in press.
20. Yuasa, H.J.; Ball, H.J.; Ho, Y.F.; Austin, C.J.; Whittington, C.M.; Belov, K.; Maghzal, G.J.; Jermiin, L.S.; Hunt, N.H. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials. Comp. Biochem. Physiol. B. Biochem. Mol. Biol., 2009, 153(2), 137-144.
21. Prendergast, G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene., 2008, 27(28), 3889-3900. (Pubitemid 351913639)
22. Muller, A.J.; DuHadaway, J.B.; Sutanto-Ward, E.; Donover, P.S.; Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nature. Med., 2005, 11, 312-319. (Pubitemid 40460560)
23. Banerjee, T.; DuHadaway, J.B.; Gaspari, P.; Sutanto-Ward, E.; Munn, D.H.; Mellor, A.L.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J. Antitumor properties of chemopreventive natural product brassinin are based upon inhibition of indoleamine 2,3-dioxygenase (IDO). Oncogene., 2008, 27(20), 2851-2857.
24. Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J.M.; DuHadaway, J.B.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3- dioxygenase. J. Med. Chem., 2008, 51(16), 4968-4977.
25. Kumar, S.; Malachowski, W.P.; Duhadaway, J.B.; Lalonde, J.M.; Carroll, P.J.; Jaller, D.; Metz, R.; Prendergast, G.C.; Muller, A.J. Indoleamine 2,3- dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J. Med. Chem., 2008, 51(6), 1706-1718. (Pubitemid 351438852)
26. Koblish, H.K.; Hansbury, M.J.; Bowman, K.J.; Yang, G.; Neilan, C.L.; Haley, P.J.; Burn, T.C.; Waeltz, P.; Sparks, R.B.; Yue, E.W.; Combs, A.P.; Scherle, P.A.; Vaddi, K.; Fridman, J.S. Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors. Mol. Cancer. Ther., 2010.
27. Hou, D.Y.; Muller, A.J.; Sharma, M.D.; DuHadaway, J.; Banerjee, T.; Johnson, M.; Mellor, A.L.; Prendergast, G.C.; Munn, D.H. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyltryptophan correlates with antitumor responses. Cancer. Res., 2007, 67(2), 792-801. (Pubitemid 46192220)
28. Muller, A.J.; Sharma, M.D.; Chandler, P.R.; Duhadaway, J.B.; Everhart, M.E.; Johnson, B.A. 3rd; Kahler, D.J.; Pihkala, J.; Soler, A.P.; Munn, D.H.; Prendergast, G.C.; Mellor, A.L. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(44), 17073-17078.
29. Baban, B.; Chandler, P.R.; Sharma, M.D.; Pihkala, J.; Koni, P.A.; Munn, D.H.; Mellor, A.L. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol., 2009, 183(4), 2475-2483.
30. Sharma, M.D.; Hou, D.Y.; Liu, Y.; Koni, P.A.; Metz, R.; Chandler, P.; Mellor, A.L.; He, Y.; Munn, D.H. Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood., 2009, 113(24), 6102-6111.
31. Munn, D.H.; Mellor, A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest., 2007, 117(5), 1147-1154. (Pubitemid 46718399)
32. Witkiewicz, A.K.; Costantino, C.L.; Metz, R.; Muller, A.J.; Prendergast, G.C.; Yeo, C.J.; Brody, J.R. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J. Am. Coll. Surg., 2009, 208(5), 781-787; discussion 787-789.
33. Muller, A.J.; Scherle, P.A. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer., 2006, 6(8), 613-625. (Pubitemid 44140859)
34. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet., 2001, 357(9255), 539-545. (Pubitemid 32173595)
35. Peek, R.M.; Mohla, S.; DuBois, R.N. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a National Cancer Institute-sponsored meeting. Cancer. Res., 2005, 65, 8583-8586. (Pubitemid 41377339)
36. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity., 2004, 21(2), 137-148. (Pubitemid 39094044)
37. Muller, A.J.; DuHadaway, J.B.; Jaller, D.; Curtis, P.; Metz, R.; Prendergast, G.C. Immunotherapeutic suppression of IDO and tumor growth by ethyl pyruvate. Cancer. Res., 2010, in. press.
38. Koebel, C.M.; Vermi, W.; Swann, J.B.; Zerafa, N.; Rodig, S.J.; Old, L.J.; Smyth, M.J.; Schreiber, R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature., 2007, 450(7171), 903-907. (Pubitemid 350231320)
39. Shankaran, V.; Ikeda, H.; Bruce, A.T.; White, J.M.; Swanson, P.E.; Old, L.J.; Schreiber, R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature., 2001, 410(6832), 1107-1111. (Pubitemid 32391043)
40. Basu, G.D.; Tinder, T.L.; Bradley, J.M.; Tu, T.; Hattrup, C.L.; Pockaj, B.A.; Mukherjee, P. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J. Immunol., 2006, 177(4), 2391-2402. (Pubitemid 44201000)
41. Lee, S.Y.; Choi, H.K.; Lee, K.J.; Jung, J.Y.; Hur, G.Y.; Jung, K.H.; Kim, J.H.; Shin, C.; Shim, J.J.; In, K.H.; Kang, K.H.; Yoo, S.H. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J. Immunother., 2009, 32(1), 22-28.
42. Schroecksnadel, K.; Winkler, C.; Duftner, C.; Wirleitner, B.; Schirmer, M.; Fuchs, D. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin. Rheumatol., 2006, 25(3), 334-337.
43. Boissier, M.C.; Feng, X.Z.; Carlioz, A.; Roudier, R.; Fournier, C. Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann. Rheum. Dis., 1987, 46(9), 691-700. (Pubitemid 17123503)
44. Bianco, N.R.; Kim, S.H.; Ruffner, M.A.; Robbins, P.D. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis. Rheum., 2009, 60(2), 380-389.
45. Criado, G.; Simelyte, E.; Inglis, J.J.; Essex, D.; Williams, R.O. Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. Arthritis. Rheum., 2009, 60(5), 1342-1351.
46. Jaen, O.; Rulle, S.; Bessis, N.; Zago, A.; Boissier, M.C.; Falgarone, G. Dendritic cells modulated by innate immunity improve collagen-induced arthritis and induce regulatory T cells in vivo. Immunology., 2009, 126(1), 35-44.
47. Park, M.J.; Min, S.Y.; Park, K.S.; Cho, Y.G.; Cho, M.L.; Jung, Y.O.; Park, H.S.; Chang, S.H.; Cho, S.G.; Min, J.K.; Park, S.H.; Kim, H.Y. Indoleamine 2,3-dioxygenase-expressing dendritic cells are involved in the generation of CD4+CD25+ regulatory T cells in Peyer's patches in an orally tolerized, collagen-induced arthritis mouse model. Arthritis. Res. Ther., 2008, 10(1), R11.
48. Seo, S.K.; Choi, J.H.; Kim, Y.H.; Kang, W.J.; Park, H.Y.; Suh, J.H.; Choi, B.K.; Vinay, D.S.; Kwon, B.S. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat. Med., 2004, 10(10), 1088-1094. (Pubitemid 39424870)
49. Szanto, S.; Koreny, T.; Mikecz, K.; Glant, T.T.; Szekanecz, Z.; Varga, J. Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice. Arthritis. Res. Ther., 2007, 9(3), R50.
50. Kouskoff, V.; Korganow, A.S.; Duchatelle, V.; Degott, C.; Benoist, C.; Mathis, D. Organ-specific disease provoked by systemic autoimmunity. Cell., 1996, 87(5), 811-822. (Pubitemid 26404281)
51. Scott, G.N.; DuHadaway, J.; Pigott, E.; Ridge, N.; Prendergast, G.C.; Muller, A.J.; Mandik-Nayak, L. The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J. Immunol., 2009, 182(12), 7509-7517.
52. Zhu, L.; Ji, F.; Wang, Y.; Zhang, Y.; Liu, Q.; Zhang, J.Z.; Matsushima, K.; Cao, Q.; Zhang, Y. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J. Immunol., 2006, 177(11), 8226-8233. (Pubitemid 44846344)
53. Cherayil, B.J. Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm. Bowel. Dis., 2009, 15(9), 1391-1396.
54. Torres, M.I.; Lopez-Casado, M.A.; Lorite, P.; Rios, A. Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease. Clin. Exp. Immunol., 2007, 148(3), 419-424. (Pubitemid 46701028)
55. Wolf, A.M.; Wolf, D.; Rumpold, H.; Moschen, A.R.; Kaser, A.; Obrist, P.; Fuchs, D.; Brandacher, G.; Winkler, C.; Geboes, K.; Rutgeerts, P.; Tilg, H. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin. Immunol., 2004, 113(1), 47-55. (Pubitemid 39468267)
56. Xu, H.; Oriss, T.B.; Fei, M.; Henry, A.C.; Melgert, B.N.; Chen, L.; Mellor, A.L.; Munn, D.H.; Irvin, C.G.; Ray, P.; Ray, A. Indoleamine 2,3- dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc. Natl. Acad. Sci. U. S. A., 2008, 105(18), 6690-6695. (Pubitemid 351754568)
57. Odemuyiwa, S.O.; Ebeling, C.; Duta, V.; Abel, M.; Puttagunta, L.; Cravetchi, O.; Majaesic, C.; Vliagoftis, H.; Moqbel, R. Tryptophan catabolites regulate mucosal sensitization to ovalbumin in respiratory airways. Allergy., 2009, 64(3), 488-492.
58. Taher, Y.A.; Piavaux, B.J.; Gras, R.; van Esch, B.C.; Hofman, G.A.; Bloksma, N.; Henricks, P.A.; van Oosterhout, A.J. Indoleamine 2,3- dioxygenase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model. J. Allergy. Clin. Immunol., 2008, 121(4), 983-991 e982.
59. Grohmann, U.; Volpi, C.; Fallarino, F.; Bozza, S.; Bianchi, R.; Vacca, C.; Orabona, C.; Belladonna, M.L.; Ayroldi, E.; Nocentini, G.; Boon, L.; Bistoni, F.; Fioretti, M.C.; Romani, L.; Riccardi, C.; Puccetti, P. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat. Med., 2007, 13(5), 579-586. (Pubitemid 46828479)
60. Hayashi, T.; Beck, L.; Rossetto, C.; Gong, X.; Takikawa, O.; Takabayashi, K.; Broide, D.H.; Carson, D.A.; Raz, E. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest., 2004, 114(2), 270-279. (Pubitemid 39071632)
61. Gordon, J.R.; Li, F.; Nayyar, A.; Xiang, J.; Zhang, X. CD8 alpha+, but not CD8 alpha-, dendritic cells tolerize Th2 responses via contact-dependent and -independent mechanisms, and reverse airway hyperresponsiveness, Th2, and eosinophil responses in a mouse model of asthma. J. Immunol., 2005, 175(3), 1516-1522. (Pubitemid 41023052)
62. Prendergast, G.C.; Metz, R.; Muller, A.J. Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway Amer. J. Pathol., 2010, in. press.
63. Harrington, L.; Srikanth, C.V.; Antony, R.; Rhee, S.J.; Mellor, A.L.; Shi, H.N.; Cherayil, B.J. Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitis. Infect. Immun., 2008, 76(7), 3045-3053.